These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 14572746)

  • 1. Intermittent maximal androgen blockade in patients with metastatic prostate cancer: an EORTC feasibility study.
    Albrecht W; Collette L; Fava C; Kariakine OB; Whelan P; Studer UE; De Reijke TM; Kil PJ; Rea LA
    Eur Urol; 2003 Nov; 44(5):505-11. PubMed ID: 14572746
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Undetectable level of prostate specific antigen (PSA) nadir predicts PSA biochemical failure in local prostate cancer with delayed-combined androgen blockade.
    Soga N; Arima K; Sugimura Y
    Jpn J Clin Oncol; 2008 Sep; 38(9):617-22. PubMed ID: 18697759
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of localized prostate cancer with intermittent triple androgen blockade: preliminary results in 110 consecutive patients.
    Leibowitz RL; Tucker SJ
    Oncologist; 2001; 6(2):177-82. PubMed ID: 11306729
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Intermittent androgen deprivation treatment of prostate cancer restarted at low level of serum prostate specific antigen: a pilot study].
    Maekawa S; Maegawa M; Ushida H; Inoue K; Kaneko Y; Ohmori K; Nishimura K
    Hinyokika Kiyo; 2001 Aug; 47(8):553-5. PubMed ID: 11579594
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prostate-cancer-specific survival and clinical progression-free survival in men with prostate cancer treated intermittently with testosterone-inactivating pharmaceuticals.
    Scholz M; Lam R; Strum S; Jennrich R; Johnson H; Trilling T
    Urology; 2007 Sep; 70(3):506-10. PubMed ID: 17905106
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
    Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K
    BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostate-specific antigen half-life and pretreatment prostate-specific antigen: crucial predictors for prostate-specific antigen trend in delayed-combined androgen blockade therapy.
    Soga N; Onishi T; Arima K; Sugimura Y
    Int J Urol; 2007 Mar; 14(3):192-6; discussion 197. PubMed ID: 17430253
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Finasteride and bicalutamide as primary hormonal therapy in patients with advanced adenocarcinoma of the prostate.
    Tay MH; Kaufman DS; Regan MM; Leibowitz SB; George DJ; Febbo PG; Manola J; Smith MR; Kaplan ID; Kantoff PW; Oh WK
    Ann Oncol; 2004 Jun; 15(6):974-8. PubMed ID: 15151957
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tissue polypeptide-specific antigen (TPS) determinations before and during intermittent maximal androgen blockade in patients with metastatic prostatic carcinoma.
    Kil PJ; Goldschmidt HM; Wieggers BJ; Kariakine OB; Studer UE; Whelan P; Hetherington J; de Reijke TM; Hoekstra JW; Collette L
    Eur Urol; 2003 Jan; 43(1):31-8. PubMed ID: 12507541
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The long-term results with delayed-combined androgen blockade therapy in local or locally advanced prostate cancer.
    Soga N; Hori Y; Ogura Y; Hayashi N; Sugimura Y
    Jpn J Clin Oncol; 2012 Jun; 42(6):534-40. PubMed ID: 22438406
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intermittent androgen suppression for prostate cancer: Canadian Prospective Trial and related observations.
    Bruchovsky N; Klotz LH; Sadar M; Crook JM; Hoffart D; Godwin L; Warkentin M; Gleave ME; Goldenberg SL
    Mol Urol; 2000; 4(3):191-9;discussion 201. PubMed ID: 11062374
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intermittent androgen suppression in the management of prostate cancer.
    Crook JM; Szumacher E; Malone S; Huan S; Segal R
    Urology; 1999 Mar; 53(3):530-4. PubMed ID: 10096379
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Maximal androgen blockade for patients with metastatic prostate cancer: outcome of a controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy. Casodex Combination Study Group.
    Schellhammer P; Sharifi R; Block N; Soloway M; Venner P; Patterson AL; Sarosdy M; Vogelzang N; Jones J; Kolvenbag G
    Urology; 1996 Jan; 47(1A Suppl):54-60; discussion 80-4. PubMed ID: 8560679
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intermittent androgen deprivation: update of cycling characteristics in patients without clinically apparent metastatic prostate cancer.
    Grossfeld GD; Chaudhary UB; Reese DM; Carroll PR; Small EJ
    Urology; 2001 Aug; 58(2):240-5. PubMed ID: 11489710
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intermittent androgen deprivation therapy may prolong the duration of androgen dependence of well-differentiated prostate cancer.
    Kaneko Y; Maekawa S; Arakaki R; Okada Y; Terada N; Nishimura K
    Hinyokika Kiyo; 2006 Apr; 52(4):259-64. PubMed ID: 16686352
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined androgen blockade with bicalutamide for advanced prostate cancer: long-term follow-up of a phase 3, double-blind, randomized study for survival.
    Akaza H; Hinotsu S; Usami M; Arai Y; Kanetake H; Naito S; Hirao Y;
    Cancer; 2009 Aug; 115(15):3437-45. PubMed ID: 19536889
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intermittent androgen suppression in the treatment of prostate cancer: a preliminary report.
    Goldenberg SL; Bruchovsky N; Gleave ME; Sullivan LD; Akakura K
    Urology; 1995 May; 45(5):839-44; discussion 844-5. PubMed ID: 7538246
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intermittent complete androgen blockade in metastatic prostate cancer.
    Rambeaud JJ
    Eur Urol; 1999; 35 Suppl 1():32-6. PubMed ID: 10081701
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intermittent versus continuous total androgen blockade in the treatment of patients with advanced hormone-naive prostate cancer: results of a prospective randomized multicenter trial.
    de Leval J; Boca P; Yousef E; Nicolas H; Jeukenne M; Seidel L; Bouffioux C; Coppens L; Bonnet P; Andrianne R; Wlatregny D
    Clin Prostate Cancer; 2002 Dec; 1(3):163-71. PubMed ID: 15046691
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intermittent androgen suppression in prostate cancer: an update of the Vancouver experience.
    Pether M; Goldenberg SL; Bhagirath K; Gleave M
    Can J Urol; 2003 Apr; 10(2):1809-14. PubMed ID: 12773232
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.